HMRI and Novartis Australia sign MoU to expedite medical research
The Hunter Medical Research Institute (HMRI) has signed a memorandum of understanding (MoU) with Novartis Australia for expediting medical research…
The Hunter Medical Research Institute (HMRI) has signed a memorandum of understanding (MoU) with Novartis Australia for expediting medical research…
The European Commission (EC) has granted marketing authorisation to BridgeBio Pharma’s selective small molecule, acoramidis, under the brand name Beyonttra,…
The US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) of Lupin’s Sacubitril and Valsartan…
With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market…
Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, marking it as the first treatment in the country authorised to…
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) stabiliser, to treat…
On November 16, at the American Heart Association (AHA) 2024 Annual Scientific Sessions in Chicago, IL, US, clinical trial results…
Lexicon Pharmaceuticals has entered a licensing agreement with Viatris, granting the latter exclusive rights to commercialise sotagliflozin in all indications…
The results of two subanalyses of the PACMAN-AMI trial were presented on the final day (2 September) of the European…
On 31 August, at this year’s European Society of Cardiology (ESC) conference, during a late-breaking science session on the topic…